PR Newswire·Jul 15, 2026, 10:10 AM ET

Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity

Azitra, Inc. announced positive results from two ex vivo human skin studies evaluating its ATR-COSF program, a supernatant formulation containing recombinant human filaggrin domain (rHDfilaggrin) derived from engineered S. epidermidis.
The first study demonstrated that multiple doses of the rHDfilaggrin formulation improved penetration & distribution into the stratum granulosum layer compared to prior single-dose experiments, with increased concentrations observed in both the stratum corneum & stratum granulosum.
Safety testing confirmed the 2% lyophilized supernatant formulation in a hydrogel is non-irritating & non-corrosive to skin & eyes.
The second study showed the hydrogel formulation increased skin elasticity in a dose-dependent manner, with a 0.28% w/w concentration restoring elasticity to levels historically seen in healthy skin.
Samples treated with 0.3% w/w supernatant exhibited approximately two times the elasticity of placebo-treated samples, indicating potential for reducing fine lines & wrinkles.
Azitra plans to optimize formulations & conduct further ex vivo wrinkle model testing before initiating human studies designed to demonstrate visible wrinkle reduction benefits.